These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 20430174)

  • 1. Mycophenolic acid trough level measurements and clinical outcomes in kidney transplantation recipients on a fixed dose (1.5 g/d) of mycophenolate mofetil in Korea.
    Lee S; Shin M; Kim E; Kim JM; Moon J; Jung G; Choi G; Kwon C; Joh J; Lee S; Kim S
    Transplant Proc; 2010 Apr; 42(3):793-6. PubMed ID: 20430174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolic acid trough levels after kidney transplantation in a cyclosporine-free protocol.
    Smak Gregoor PJ; van Gelder T; van Besouw NM; van der Mast BJ; Hesse CJ; IJzermans JN; Weimar W
    Transpl Int; 2000; 13 Suppl 1():S333-5. PubMed ID: 11112026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.
    van Gelder T; Hilbrands LB; Vanrenterghem Y; Weimar W; de Fijter JW; Squifflet JP; Hené RJ; Verpooten GA; Navarro MT; Hale MD; Nicholls AJ
    Transplantation; 1999 Jul; 68(2):261-6. PubMed ID: 10440399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
    Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
    Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inadequate mycophenolic acid exposure and acute rejection in kidney transplantation.
    Sánchez-Fructuoso AI; de la Higuera MA; Giorgi M; Ramos F; Garcia Ledesma P; Calvo N; Pérez-Flores I; Barrientos A
    Transplant Proc; 2009; 41(6):2104-5. PubMed ID: 19715844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients.
    Merkel U; Lindner S; Vollandt R; Sperschneider H; Balogh A
    Int J Clin Pharmacol Ther; 2005 Aug; 43(8):379-88. PubMed ID: 16119513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation.
    van Gelder T; Silva HT; de Fijter H; Budde K; Kuypers D; Mamelok RD; Armstrong VW; Oellerich M
    Ther Drug Monit; 2011 Apr; 33(2):155-64. PubMed ID: 21383657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
    Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE
    Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical application of monitoring mycophenolic acid trough concentration in heart transplant recipients--single center's experience.
    Zakliczyński M; Szewczyk M; Zakliczyńska H; Zembala M
    Ann Transplant; 2005; 10(2):38-45. PubMed ID: 16218032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients.
    Demirbaş A; Tuncer M; Yavuz A; Gürkan A; Kaçar S; Cetinkaya R; Tekin S; Akbaş SH; Akaydin M; Ersoy F; Yakupoğlu G
    Transplant Proc; 2004; 36(1):175-7. PubMed ID: 15013338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
    Sarwal MM; Vidhun JR; Alexander SR; Satterwhite T; Millan M; Salvatierra O
    Transplantation; 2003 Nov; 76(9):1331-9. PubMed ID: 14627912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil in living donor renal allograft recipients.
    Park K; Moon JI; Kim SI; Kim YS
    Transplant Proc; 1999; 31(1-2):1133. PubMed ID: 10083506
    [No Abstract]   [Full Text] [Related]  

  • 15. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
    Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graft outcome and mycophenolic acid trough level monitoring in kidney transplantation.
    Sánchez Fructuoso AI; de la Higuera MA; Garcia-Ledesma P; Giorgi M; Ramos F; Calvo N; Pérez-Flores I; Barrientos A
    Transplant Proc; 2009; 41(6):2102-3. PubMed ID: 19715843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients.
    Jirasiritham S; Sumethkul V; Mavichak V; Na-Bangchang K
    Transplant Proc; 2004 Sep; 36(7):2076-8. PubMed ID: 15518751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcineurin inhibitor-free immunosuppressive strategy in elderly recipients of renal allografts from deceased donors: 1-year results from a prospective single center trial.
    Arbogast HP; Hoffmann JN; Illner WD; Hillebrand GF; Fischereder M; Jauch KW; Land W
    Transplant Proc; 2009; 41(6):2529-32. PubMed ID: 19715968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
    Mardigyan V; Tchervenkov J; Metrakos P; Barkun J; Deschenes M; Cantarovich M
    Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.